Both in Pharmaceuticals
PDS Biotechnology vs Genelux
Over the past year PDSB returned +37.0% and GNLX returned −76.5%; their daily moves had a correlation of 0.12.
PDSB +37.0% GNLX −76.5%Growth of $1, one year, split-adjusted
| Metric | PDSB | GNLX |
|---|---|---|
| Price | $1.28 | $1.94 |
| Market cap | $92.8M | $87.8M |
| Today | −9.22% | +1.04% |
| 1 month | +22.5% | −23.6% |
| 6 months | +20.8% | −32.4% |
| Year to date | +66.3% | −55.5% |
| 1 year | +37.0% | −76.5% |
| Revenue growth (YoY) | — | — |
| Gross margin | — | — |
| Net margin | — | — |
| P/E (TTM) | — | — |
| Price / sales | — | 10,972.0× |
| Net cash | $1.2M | $18.7M |
| Dividend yield | — | — |
| Volatility (60d) | 229.1% | 65.7% |
| Short % of float | 8.6% | 12.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).